Enlaza's War-Lock platform uses covalent-acting protein drugs with non-natural amino acids, enhancing therapeutic windows for safer, effective treatments. The partnership targets autoimmune diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback